Recent Highlights from the Healthcare Sector: Complementary Research on BioMarin, Seattle Genetics, Globus Medical, Nymox and Progenics
NEW YORK, May 11, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Moments ago, Analysts Review released new research updates concerning several important developing situations including BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Seattle Genetics Inc. (NASDAQ: SGEN), Globus Medical Inc. (NYSE: GMED), Nymox Pharmaceutical Corporation (NASDAQ: NYMX), and Progenics Pharmaceuticals Inc. (NASDAQ: PGNX). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
--
Today's update concerns the following companies:
============
Full PDF Download Links (you may have to copy and paste the following links into your browser):
BMRN Research Report: ( http://get.analystsreview.com/pdf/?c=BioMarin%20Pharmaceutical%20Inc.&d=11-May-2015&s=BMRN ),
SGEN Research Report: ( http://get.analystsreview.com/pdf/?c=Seattle%20Genetics&d=11-May-2015&s=SGEN ),
GMED Research Report: ( http://get.analystsreview.com/pdf/?c=Globus%20Medical&d=11-May-2015&s=GMED ),
NYMX Research Report: ( http://get.analystsreview.com/pdf/?c=Nymox%20Pharmaceutical%20Corporation&d=11-May-2015&s=NYMX ),
PGNX Research Report: ( http://get.analystsreview.com/pdf/?c=Progenics%20Pharmaceuticals&d=11-May-2015&s=PGNX ).
============
--
Analyst Update: Clinical Trialsand Earnings
U.S. stocks advanced sharply on Friday, after stronger employment data for April suggested the US economy is gaining traction again. The Dow Jones Industrial Average rose 1.49%, to close at 18,191.11, the S&P 500 gained 1.35%, to 2,116.10, and the NASDAQ Composite finished the session at 5,003.55, up 1.17%. European stocks rallied on Friday, lifted by the UK election results, which showed the Conservative Party unexpectedly sweeping into power again. Germany's DAX 30 rose 2.65%, France's CAC 40 advanced 2.48%, and the London's FTSE 100 closed 2.32% higher on Friday. Meanwhile, Asian markets surged on Friday after losing ground in the last few days. The Shanghai Composite, Japan's Nikkei, and Hong Kong's Hang Seng all posted gains on Friday.
BioMarin Pharmaceutical Inc. (BioMarin) on April 30, 2015 announced its financial results for the first quarter ended March 31, 2015. Total BioMarin revenue was $203.3 million for the first quarter of 2015, an increase of 34% from the first quarter of 2014.
Seattle Genetics, Inc. (Seattle Genetics) on April 30, 2015 announced its first quarter 2015 financial results. The Company reported total revenues in the first quarter of 2015 of $82.2 million, compared to $68.3 million in the first quarter of 2014. The sales represented a growth of 20.3% over last year's first quarter and surpassed the Zacks consensus estimate of $74 million.
Globus Medical, Inc. on May 5, 2015 reported that its first quarter 2015 global sales of $131.6 million were up 15.2% from $114.2 million reported in the first quarter of last fiscal. The Company also reported an increase in net income of 16.6% to aggregate $24.6 million compared to same period last year reported number of $21.1 million.
Nymox Pharmaceutical Corporation (Nymox) announced the long term clinical trial results from the Company's NX-1207 Phase 2 prostate cancer study NX03-0040. The new results establish statistically significant (p=.0067) better outcomes at up to 2.8 years for NX-1207 treated patients compared to controls.
Progenics Pharmaceuticals, Inc. (Progenics) on May 6, 2015 announced results of operations for the first quarter 2015 (period ended March 31, 2015). The Company reported a net loss of $10.3 million or $0.15 per diluted share for the quarter, as compared to net loss of 9.3 million or $0.15 per diluted share for the same quarter prior year.
--
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
--
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider, represented by a registered analyst has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article